Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,241 to 2,260 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Influenza Vaccine vs Placebo: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens | 35 of 1,792 62 of 1,817 | -1.5 points -2.5 to -0.4 | 3,609 | NCT00566345 Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII) |
| Intervention vs Control: Prevalence of Chronic Kidney Disease (CKD) | 361 of 2,100 248 of 1,505 | 0.7 points -1.8 to 3.2 | 3,605 | NCT01864603 Sustainable East Africa Research in Community Health |
| Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Non-Coronary Artery Bypass Grafting-Related Major Bleeding | 89 of 1,800 149 of 1,802 | -3.3 points -5.0 to -1.7 | 3,602 | NCT00433966 Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction |
| Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Major Adverse Cardiovascular Events | 379 of 1,800 377 of 1,802 | 0.1 points -2.5 to 2.8 | 3,602 | NCT00433966 Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction |
| Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Major Adverse Cardiovascular Events | 98 of 1,800 99 of 1,802 | -0.0 points -1.5 to 1.4 | 3,602 | NCT00433966 Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction |
| Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding Events | 166 of 1,800 218 of 1,802 | -2.9 points -4.9 to -0.9 | 3,602 | NCT00433966 Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction |
| RSV Season 1: Clesrovimab 105 mg vs RSV Season 1: Placebo: RSV Season 1: Number of Participants With RSV-Associated MALRI | 64 of 2,398 77 of 1,201 | -3.7 points -5.4 to -2.3 | 3,599 | NCT04767373 Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) |
| RSV Season 1: Clesrovimab 105 mg vs RSV Season 1: Placebo: RSV Season 1: Number of Participants With Respiratory Syncytial Virus (RSV)-Associated Medically Attended Lower Respiratory Infection (MALRI) | 60 of 2,398 74 of 1,201 | -3.7 points -5.3 to -2.2 | 3,599 | NCT04767373 Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) |
| RSV Season 1: Clesrovimab 105 mg vs RSV Season 1: Placebo: RSV Season 1: Number of Participants With RSV-Associated Hospitalization | 9 of 2,398 28 of 1,201 | -2.0 points -3.0 to -1.2 | 3,599 | NCT04767373 Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: All Cause Mortality at 30 Days | 18 of 2,708 3 of 885 | 0.3 points -0.4 to 0.8 | 3,593 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: 30-day Composite Major Adverse Cardiac Event (MACE) | 256 of 2,706 83 of 886 | 0.1 points -2.3 to 2.2 | 3,592 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| Aclidinium Bromide vs Placebo: Number of Participants With Major Adverse Cardiovascular Event (MACE) - on Study Analysis | 69 of 1,791 76 of 1,798 | -0.4 points -1.7 to 0.9 | 3,589 | NCT01966107 Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. |
| Aclidinium Bromide vs Placebo: Number of Participants With Major Adverse Cardiovascular Event (MACE) or Other Serious Cardiovascular Events of Interest - On-study Analysis | 168 of 1,791 160 of 1,798 | 0.5 points -1.4 to 2.4 | 3,589 | NCT01966107 Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. |
| Aclidinium Bromide vs Placebo: deaths from any cause | 75 of 1,791 64 of 1,798 | 0.6 points -0.6 to 1.9 | 3,589 | NCT01966107 Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. |
| Aclidinium Bromide vs Placebo: serious adverse events | 409 of 1,791 356 of 1,798 | 3.0 points 0.4 to 5.7 | 3,589 | NCT01966107 Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Rate of Stent Thrombosis | 16 of 2,695 7 of 883 | -0.2 points -1.1 to 0.4 | 3,578 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| M72AS01 Group vs Control Group: Number of Subjects With Serious Adverse Events (SAEs). | 51 of 1,786 62 of 1,787 | -0.6 points -1.8 to 0.5 | 3,573 | NCT01755598 Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults |
| M72AS01 Group vs Control Group: Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) | 2 of 1,786 6 of 1,787 | -0.2 points -0.6 to 0.1 | 3,573 | NCT01755598 Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults |
| M72AS01 Group vs Control Group: Number of Subjects With Any Unsolicited Adverse Events (AEs). | 1,207 of 1,786 816 of 1,787 | 21.9 points 18.7 to 25.1 | 3,573 | NCT01755598 Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults |
| M72AS01 Group vs Control Group: deaths from any cause | 19 of 1,786 28 of 1,787 | -0.5 points -1.3 to 0.3 | 3,573 | NCT01755598 Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults |
Code
curl "https://conductscience.org/api/comparisons/v1?page=113"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=113
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00566345-07e0ff93",
"title": "Influenza Vaccine vs Placebo: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens",
"summary": "35 of 1792 against 62 of 1817; risk difference -1.5 points, 95% interval -2.5 to -0.4; NCT00566345, Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)",
"record": "/library/comparisons/NCT00566345-07e0ff93",
"nct_id": "NCT00566345",
"kind": "outcome",
"participants": 3609,
"risk_difference": {
"value": -0.014590929416620803,
"lower": -0.02544081129984007,
"upper": -0.004038257515273909
},
"group_1": "35 of 1,792",
"group_2": "62 of 1,817",
"difference": "-1.5 points",
"interval": "-2.5 to -0.4",
"trial_title": "Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)"
},
{
"id": "NCT01864603-1a6b1362",
"title": "Intervention vs Control: Prevalence of Chronic Kidney Disease (CKD)",
"summary": "361 of 2100 against 248 of 1505; risk difference 0.7 points, 95% interval -1.8 to 3.2; NCT01864603, Sustainable East Africa Research in Community Health",
"record": "/library/comparisons/NCT01864603-1a6b1362",
"nct_id": "NCT01864603",
"kind": "outcome",
"participants": 3605,
"risk_difference": {
"value": 0.007120708748615701,
"lower": -0.017882447636257383,
"upper": 0.03161252654836551
},
"group_1": "361 of 2,100",
"group_2": "248 of 1,505",
"difference": "0.7 points",
"interval": "-1.8 to 3.2",
"trial_title": "Sustainable East Africa Research in Community Health"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=114",
"request_id": "l_QTALtvclvv_r7I"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant